Patent · US Active

Soluble fibroblast growth factor receptor 3 (SFGFR3) polypeptides and uses thereof

US10294289B2 · kind B2 · utility

5Cited by

20References

21Claims

0Family size

Assignees

Therachon SAS · FR
INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) · FR
Université de Nice Sophia-Antipolis · FR

Inventors

Elvire Gouze · Vallauris, FR
Stéphanie Garcia · Nice, FR

Key dates

Filing date	Apr 2, 2018
Grant date	May 21, 2019
Priority date	—
Expiry date	Apr 2, 2038

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K38/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention features soluble fibroblast growth factor receptor 3 (sFGFR3) polypeptides. The invention also features methods of using sFGFR3 polypeptides to treat skeletal growth retardation disorders, such as achondroplasia.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.